PathAI, a global leader in AI-powered pathology, today announced the expansion of its BioPharma Laboratory Services. Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications.
The lab offers pharmaceutical companies access to unparalleled histological laboratory services and comprehensive operational support, encompassing the full end-to-end tissue processing from kitting and logistics management, tissue processing and staining across H&E, IHC, and special stains; local and remote pathology tapping into PathAIs network of >500 US board-certified pathologists; and AI-driven analysis from PathAIs menu of algorithms and clinical trial software. This integrated approach enables the streamlined, proficient, and regulatory-compliant implementation of controlled clinical trials, all within a single facility.
PathAIs BioPharma Lab has a unique combination of capabilities to enable clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to the success of their pharma partners. Over the last two years, the company has already supported Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials.
Based on successfully meeting key milestones on quality and turnaround times, PathAI is expanding and scaling its services to new trial indications and partners. The lab adheres to all relevant quality, regulatory, and compliance standards including CAP/CLIA and GCP/GCLP.
In addition to full laboratory support for clinical trials, PathAIs BioPharma Lab supports trials through its AI products and expertise with AI-powered endpoint assessment and patient enrollment. We dont just create algorithms, we stay in lock step with our pharma partners to ensure our AI products are integrated into trials appropriately, based on regulatory criteria, to enhance trial quality and efficiency, said Andy Beck, MD, PhD, CEO of PathAI.
The BioPharma Labs expertise helps reduce the impact of many challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. In addition, the lab allows pharma partners the ability to use AI without a heavy lift to implement. The lab offers most major types of instrumentation, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Importantly, the services include access to PathAIs extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner.
During my time running translational sciences in a Top 10 pharma company, I witnessed a strong need for high quality, scalable, and flexible pathology services that can further be combined with the state-of-the-art technology in digital pathology and AI, said Mike Montalto, PhD, Chief Scientific Officer, of PathAI. We took a pharma-first approach when establishing this lab and its offerings.
The BioPharma Lab will physically expand in 2024 to allow an increase in sample throughput to accommodate larger scale global phase 3 studies, as well as additional equipment to support a wider range of clinical studies.
Learn more about how PathAIs BioPharma Lab can power your next clinical trial by contacting BD@pathai.com or visiting https://www.pathai.com/clinical-trial-services/. PathAI will be at several upcoming conferences with representatives available to speak about the labs capabilities, including ESMO, SCOPE Europe (booth #4), and SCOPE Orlando (booth #206).
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com.
SVM Public Relations and Marketing Communications
View source version on newsdirect.com: https://newsdirect.com/news/pathai-announces-expansion-of-biopharma-lab-to-provide-end-to-end-central-pathology-and-histology-services-159940389
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Opinion Bulletin journalist was involved in the writing and production of this article.